Vazaprostan 0.02 10 vials

Vazaprostan is a preparation of prostaglandin E1. Improves microcirculation and peripheral circulation.

Reduces the tone of arterioles and postcapillary sphincters, reduces OPSS without changing blood pressure, increases coronary blood flow and the fraction of left ventricular ejection.

Improves the rheological properties of blood by reducing adhesion and aggregation of platelets, reducing aggregation and improving the deformability of erythrocytes, increasing fibrinolytic activity and reducing blood viscosity.

It has an effect on metabolism, increases the utilization of glucose and oxygen, inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates the synthesis of proteins, has a beneficial effect on lipid metabolism (suppression of cholesterol synthesis and decrease in LDL concentration), inhibits the proliferation and mitosis of smooth muscle cells.

Against the backdrop of treatment, Vasaprostan decreases the severity of the pain syndrome at rest, accelerates the healing of trophic ulcers, and a remission occurs during the course of the disease.

Indications:

Treatment of chronic obliterating diseases of arteries of III and IV stages.

Contraindications:

• chronic heart failure in the stage of decompensation;
• Acute myocardial infarction and post-infarction period for 6 months;
• marked violations of the rhythm of the heart;
• acute circulatory failure (shock, vascular collapse);
• severe arterial hypotension (systolic blood pressure less than 90 mm Hg);
• pronounced violations of the liver function;
• Stomach ulcer and duodenal ulcer;
• Hypersensitivity to the drug.

Suggested Use:

Vasaprostan can be administered in / a and / in.

To obtain a solution for intra-arterial administration, 20 μg (the contents of one ampoule) should be dissolved in 50 ml of saline. When carrying out the intravenous infusion, 25 ml of the resulting solution (10 μg alprostadil) should be administered within 60-120 minutes using a special device for intravenous infusion. If necessary (especially with necrosis), the dose can be increased to 50 ml (20 μg). If the drug is administered through an established catheter, the infusion is administered for 12 hours at a dose of 0.1-0.6 ng / kg body weight per minute (corresponding to 12.5-25 ml of a solution of Vasaprostan).

To obtain a solution for intravenous administration, 40 μg (the contents of two ampoules) of dry matter should be dissolved in 50-250 ml of physiological solution and injected solution in / in the drip for 2 hours 2 times / day, or dissolve 60 μg (the contents of 3 ampoules) in 50-250 ml of physiological solution and injected / drip for 3 hours 1 time / day.

In patients with impaired renal function (creatinine concentration more than 1.5 mg / dl) IV injection of Vazaprostan should be started with 10 mg 2 times / day, the duration of each infusion is 2 hours. With good tolerability for 2-3 days, the dose can be increased to usual. The duration of one course of treatment should not exceed 4 weeks.

Side effects:

From the cardiovascular system: palpitation, arterial hypotension, headache; in a few cases - increased rates of angina pectoris, the development of pulmonary edema, the phenomena of heart failure.

From the digestive system: dyspeptic phenomena, increased activity of hepatic transaminases.

Other: leukopenia, leukocytosis; with prolonged therapy (more than 4 weeks) in isolated cases, hyperostosis of tubular bones.

Local reactions: edema, hyperemia, pain at the injection site.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!